Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx in clinical practice

  • Data from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical practice among more than 13,000 patients [1-6]
  • The studies report on the real-world sustained efficacy, favorable safety profile, and impact on quality of life of Cosentyx over the long-term up to 2.5 years [1-6]
  • Cosentyx is backed by robust clinical evidence, including 5-year sustained efficacy and safety data across psoriasis, psoriatic arthritis and ankylosing spondylitis, and dedicated studies in the persistent manifestations of psoriasis, namely nails, scalp, palms and soles [7-10]
  • Cosentyx has a broad head-to-head study program that includes FIXTURE, CLEAR, CLARITY, SURPASS and EXCEED clinical superiority trials [11-16]

Basel, October 9, 2019 - "These extensive results confirm what has been previously observed in Phase 3 clinical trials, and support our continued use of Cosentyx in psoriatic disease, to offer patients improved symptom control and quality of life," said Prof. Matthias Augustin, Director of the Institute for Health Services Research in Dermatology and Nursing. "Real-world evidence and observational studies help to bridge the gap in knowledge that exists between clinical trials and clinical practice. They provide important insights about patient characteristics, disease severity and management. Moreover, they also support the evidence of the treatment effectiveness in the routine clinical practice."

These data are being presented at the 28th Congress of the European Academy of Dermatology and Venereology (EADV), 9-13 October 2019, Madrid, Spain.